Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future DOI Creative Commons
G. Gavazzi, Bertrand Fougère, Olivier Hanon

et al.

Expert Review of Vaccines, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Influenza causes considerable morbidity and mortality in Europe, particularly among older adults due to comorbidities, as well immunosenescence inflammaging, which contribute a diminished immune response. Vaccination remains the most effective way prevent poor outcomes; however, uptake is suboptimal many countries recommend standard vaccines despite evidence supporting better protection with enhanced (adjuvanted high-dose) vaccines. A multidisciplinary group of experts reviewed burden influenza Europe evaluated data on vaccines, providing recommendations for their use adults. The discussed barriers vaccination strategies increase uptake. Improving against relies upon increasing vaccine ensuring access that overcome age-related immunological decline. Achieving higher requires national policies facilitate equitable clear communication about eligibility. Based available evidence, offer than hospitalization complications National should prioritize over Limitations interpretation include discrepancies reporting influenza-related medical encounters, underreporting complications, lack randomized studies comparing high-dose adjuvanted

Language: Английский

Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future DOI Creative Commons
G. Gavazzi, Bertrand Fougère, Olivier Hanon

et al.

Expert Review of Vaccines, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Influenza causes considerable morbidity and mortality in Europe, particularly among older adults due to comorbidities, as well immunosenescence inflammaging, which contribute a diminished immune response. Vaccination remains the most effective way prevent poor outcomes; however, uptake is suboptimal many countries recommend standard vaccines despite evidence supporting better protection with enhanced (adjuvanted high-dose) vaccines. A multidisciplinary group of experts reviewed burden influenza Europe evaluated data on vaccines, providing recommendations for their use adults. The discussed barriers vaccination strategies increase uptake. Improving against relies upon increasing vaccine ensuring access that overcome age-related immunological decline. Achieving higher requires national policies facilitate equitable clear communication about eligibility. Based available evidence, offer than hospitalization complications National should prioritize over Limitations interpretation include discrepancies reporting influenza-related medical encounters, underreporting complications, lack randomized studies comparing high-dose adjuvanted

Language: Английский

Citations

0